Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2a Double-blind, Placebo-controlled Study to Assess the Safety and Tolerability of a Single Intravenous Dose of an Investigational Monoclonal Antibody With Code Name VIS410 in Subjects With Uncomplicated Influenza A Infection

NCT02989194 is registered in ClinicalTrials.gov with Visterra, Inc. as lead sponsor.

NCT NCT02989194
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02989194 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2a Double-blind, Placebo-controlled Study to Assess the Safety and Tolerability of a Single Intravenous Dose of an Investigational Monoclonal Antibody With Code Name VIS410 in Subjects With Uncomplicated Influenza A Infection
Lead sponsor
Visterra, Inc.
Phase
Phase 2
Overall status
Completed
Start date
January 6, 2017
Completion date
October 27, 2017
Enrollment
150 (actual)
Sites
54

Conditions

As the registry lists them; a condition with its own page is linked.

influenza